Exploring G Protein-Coupled Receptors (GPCRs) Ligand Space via Cheminformatics Approaches: Impact on Rational Drug Design
暂无分享,去创建一个
Sun Choi | Shaherin Basith | Soosung Kang | Minghua Cui | Stephani J. Y. Macalino | Jongmi Park | Nina A. B. Clavio | S. J. Y. Macalino | M. Cui | Sun Choi | S. Basith | N. A. B. Clavio | Soosung Kang | Jongmi Park | Shaherin Basith | Minghua Cui | S. J. Macalino
[1] László Kovács,et al. Structure-Based Consensus Scoring Scheme for Selecting Class A Aminergic GPCR Fragments , 2016, J. Chem. Inf. Model..
[2] T. Clark. G-Protein coupled receptors: answers from simulations , 2017, Beilstein journal of organic chemistry.
[3] Kai-Wei Chang,et al. iScreen: world’s first cloud-computing web server for virtual screening and de novo drug design based on TCM database@Taiwan , 2011, J. Comput. Aided Mol. Des..
[4] Damián Palomba,et al. Expanding the horizons of G protein-coupled receptor structure-based ligand discovery and optimization using homology models. , 2015, Chemical communications.
[5] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[6] Monya Baker,et al. Fragment-based lead discovery grows up , 2012, Nature Reviews Drug Discovery.
[7] Guodong Liu,et al. A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[8] P. Jenner. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease , 2005, Expert opinion on investigational drugs.
[9] R. Stevens,et al. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. , 2007, Science.
[10] Asher Mullard,et al. The drug-maker's guide to the galaxy , 2017, Nature.
[11] Richard S Judson,et al. In Silico Study of In Vitro GPCR Assays by QSAR Modeling. , 2016, Methods in molecular biology.
[12] Alexandre Varnek,et al. Chemoinformatics approaches to virtual screening , 2008 .
[13] Woody Sherman,et al. Selecting an Optimal Number of Binding Site Waters To Improve Virtual Screening Enrichments Against the Adenosine A2A Receptor , 2014, J. Chem. Inf. Model..
[14] Bryan L. Roth,et al. Structure of the human smoothened receptor bound to an antitumour agent , 2013, Nature.
[15] I. Piedade,et al. In silico prediction of , 2014 .
[16] A. Leslie,et al. Structure of the adenosine A2A receptor bound to an engineered G protein , 2016, Nature.
[17] K. Garcia,et al. Adrenaline-activated structure of the β2-adrenoceptor stabilized by an engineered nanobody , 2013, Nature.
[18] Peter Kolb,et al. Structure‐Based Virtual Screening for Dopamine D2 Receptor Ligands as Potential Antipsychotics , 2016, ChemMedChem.
[19] Albert C. Pan,et al. Pathway and mechanism of drug binding to G-protein-coupled receptors , 2011, Proceedings of the National Academy of Sciences.
[20] Pankaj R. Daga,et al. Structure-Based Virtual Screening of the Nociceptin Receptor: Hybrid Docking and Shape-Based Approaches for Improved Hit Identification , 2014, J. Chem. Inf. Model..
[21] John B. O. Mitchell. Machine learning methods in chemoinformatics , 2014, Wiley interdisciplinary reviews. Computational molecular science.
[22] Brian K Shoichet,et al. Structure-based drug screening for G-protein-coupled receptors. , 2012, Trends in pharmacological sciences.
[23] Alexander Heifetz,et al. Computational Methods for GPCR Drug Discovery , 2018, Methods in Molecular Biology.
[24] Ralf C. Kling,et al. GPCR crystal structures: Medicinal chemistry in the pocket. , 2015, Bioorganic & medicinal chemistry.
[25] Xiao-dan Li,et al. Discovery of novel antagonists of human neurotensin receptor 1 on the basis of ligand and protein structure. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[26] Paul A. Insel,et al. G Protein-Coupled Receptors as Targets for Approved Drugs: How Many Targets and How Many Drugs? , 2018, Molecular Pharmacology.
[27] Pablo R. Duchowicz,et al. Software and Web Resources for Computer-Aided Molecular Modeling and Drug Discovery , 2016 .
[28] Krzysztof Palczewski,et al. Organization of the G Protein-coupled Receptors Rhodopsin and Opsin in Native Membranes* , 2003, Journal of Biological Chemistry.
[29] Peter Ertl,et al. Relationships between Molecular Complexity, Biological Activity, and Structural Diversity , 2006, J. Chem. Inf. Model..
[30] Christopher G. Tate,et al. Biophysical Fragment Screening of the β1-Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design , 2013, Journal of medicinal chemistry.
[31] Ali Jazayeri,et al. Structure of class B GPCR corticotropin-releasing factor receptor 1 , 2013, Nature.
[32] T. Nikolskaya,et al. Algorithms for network analysis in systems-ADME/Tox using the MetaCore and MetaDrug platforms , 2006, Xenobiotica; the fate of foreign compounds in biological systems.
[33] A. Kruse,et al. Structural Basis for G Protein-Coupled Receptor Activation. , 2017, Biochemistry.
[34] Ali Jazayeri,et al. From G Protein-coupled Receptor Structure Resolution to Rational Drug Design* , 2015, The Journal of Biological Chemistry.
[35] J. Vilardaga. Studying ligand efficacy at G protein-coupled receptors using FRET. , 2011, Methods in molecular biology.
[36] Markus Hartenfeller,et al. DOGS: Reaction-Driven de novo Design of Bioactive Compounds , 2012, PLoS Comput. Biol..
[37] M. Babu,et al. Molecular signatures of G-protein-coupled receptors , 2013, Nature.
[38] Dingfeng Wu,et al. The recent progress in proteochemometric modelling: focusing on target descriptors, cross‐term descriptors and application scope , 2017, Briefings Bioinform..
[39] Albert C. Pan,et al. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs , 2013, Nature.
[40] Ali Jazayeri,et al. Structurally Enabled Discovery of Adenosine A2A Receptor Antagonists. , 2017, Chemical reviews.
[41] T. Schwartz,et al. Receptor structure-based discovery of non-metabolite agonists for the succinate receptor GPR91 , 2017, Molecular metabolism.
[42] Mark McGann,et al. FRED and HYBRID docking performance on standardized datasets , 2012, Journal of Computer-Aided Molecular Design.
[43] P. Argos,et al. The structure of bovine rhodopsin , 2004, Biophysics of structure and mechanism.
[44] Xiang-Qun Xie,et al. Chemogenomics knowledgebased polypharmacology analyses of drug abuse related G-protein coupled receptors and their ligands , 2013, Front. Pharmacol..
[45] D. Sejer Pedersen,et al. Bitopic Ligands and Metastable Binding Sites: Opportunities for G Protein-Coupled Receptor (GPCR) Medicinal Chemistry. , 2017, Journal of medicinal chemistry.
[46] Didier Rognan,et al. Structure‐Based Discovery of Allosteric Modulators of Two Related Class B G‐Protein‐Coupled Receptors , 2011, ChemMedChem.
[47] Hiromasa Kaneko,et al. A Mini-review on Chemoinformatics Approaches for Drug Discovery , 2015 .
[48] Chris de Graaf,et al. Snooker: A Structure-Based Pharmacophore Generation Tool Applied to Class A GPCRs , 2011, J. Chem. Inf. Model..
[49] William Thomsen,et al. Functional assays for screening GPCR targets. , 2005, Current opinion in biotechnology.
[50] Vadim Cherezov,et al. Allosteric sodium in class A GPCR signaling. , 2014, Trends in biochemical sciences.
[51] Xi Zhang,et al. Seven perspectives on GPCR H/D-exchange proteomics methods , 2017, F1000Research.
[52] K. Palczewski,et al. Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.
[53] Masahiko Nakatsui,et al. Chemical Genomics Approach for GPCR-Ligand Interaction Prediction and Extraction of Ligand Binding Determinants , 2013, J. Chem. Inf. Model..
[54] L. Luck,et al. Molecular modeling of estrogen receptor using molecular operating environment , 2007, Biochemistry and molecular biology education : a bimonthly publication of the International Union of Biochemistry and Molecular Biology.
[55] Sean Ekins,et al. Towards a gold standard: regarding quality in public domain chemistry databases and approaches to improving the situation. , 2012, Drug discovery today.
[56] David Rodríguez,et al. Molecular Docking Screening Using Agonist-Bound GPCR Structures: Probing the A2A Adenosine Receptor , 2015, J. Chem. Inf. Model..
[57] Maria F. Sassano,et al. Conformation Guides Molecular Efficacy in Docking Screens of Activated β-2 Adrenergic G Protein Coupled Receptor , 2013, ACS chemical biology.
[58] Y. Liu,et al. Methods used to study the oligomeric structure of G-protein-coupled receptors , 2017, Bioscience reports.
[59] Woody Sherman,et al. Molecular dynamics techniques for modeling G protein-coupled receptors. , 2016, Current opinion in pharmacology.
[60] Ruben Abagyan,et al. Pocketome: an encyclopedia of small-molecule binding sites in 4D , 2011, Nucleic Acids Res..
[61] Ali Jazayeri,et al. Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). , 2015, Journal of medicinal chemistry.
[62] Kenneth Jones,et al. Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.
[63] Arthur Christopoulos,et al. Structural features embedded in G protein-coupled receptor co-crystal structures are key to their success in virtual screening , 2017, PloS one.
[64] Jürgen Bajorath,et al. Chemoinformatics : concepts, methods, and tools for drug discovery , 2004 .
[65] C. Tautermann. Impact, determination and prediction of drug-receptor residence times for GPCRs. , 2016, Current opinion in pharmacology.
[66] Sean Ekins,et al. A quality alert and call for improved curation of public chemistry databases. , 2011, Drug discovery today.
[67] Olivier Michielin,et al. SwissSimilarity: A Web Tool for Low to Ultra High Throughput Ligand-Based Virtual Screening , 2016, J. Chem. Inf. Model..
[68] Yanli Wang,et al. Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review , 2012, The AAPS Journal.
[69] David Rodríguez,et al. Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists. , 2016, ACS chemical biology.
[70] G. Wynne,et al. Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists , 2015, Bioorganic & medicinal chemistry.
[71] Peter Gmeiner,et al. Muscarinic Receptors as Model Targets and Antitargets for Structure-Based Ligand Discovery , 2013, Molecular Pharmacology.
[72] J. Varghese,et al. Development of neuraminidase inhibitors as anti‐influenza virus drugs , 1999 .
[73] C. Lemmen,et al. FLEXS: a method for fast flexible ligand superposition. , 1998, Journal of medicinal chemistry.
[74] Henry Lin,et al. Structure-based discovery of opioid analgesics with reduced side effects , 2016, Nature.
[75] F. Brown. Chapter 35 – Chemoinformatics: What is it and How does it Impact Drug Discovery. , 1998 .
[76] Albert C. Pan,et al. Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor , 2012, Nature.
[77] J. Pin,et al. A virtual screening hit reveals new possibilities for developing group III metabotropic glutamate receptor agonists. , 2010, Journal of medicinal chemistry.
[78] Terry Kenakin,et al. Pharmacology in Drug Discovery and Development : Understanding Drug Response Ed. 2 , 2016 .
[79] Paul D Lyne,et al. Structure-based virtual screening: an overview. , 2002, Drug discovery today.
[80] Jean-François Gibrat,et al. Automatic modeling of mammalian olfactory receptors and docking of odorants. , 2012, Protein engineering, design & selection : PEDS.
[81] Alexander Tropsha,et al. Trust, but Verify II: A Practical Guide to Chemogenomics Data Curation , 2016, J. Chem. Inf. Model..
[82] Ruben Abagyan,et al. Docking and scoring with ICM: the benchmarking results and strategies for improvement , 2012, Journal of Computer-Aided Molecular Design.
[83] Paolo Carloni,et al. GOMoDo: A GPCRs Online Modeling and Docking Webserver , 2013, PloS one.
[84] David E. Gloriam,et al. Integrating structural and mutagenesis data to elucidate GPCR ligand binding. , 2016, Current opinion in pharmacology.
[85] Sun Choi,et al. Recent Advances in Structure-Based Drug Design Targeting Class A G Protein-Coupled Receptors Utilizing Crystal Structures and Computational Simulations. , 2018, Journal of medicinal chemistry.
[86] J. Andrew McCammon,et al. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor , 2016, Proceedings of the National Academy of Sciences.
[87] Alexander Golbraikh,et al. Application of Quantitative Structure–Activity Relationship Models of 5-HT1A Receptor Binding to Virtual Screening Identifies Novel and Potent 5-HT1A Ligands , 2014, J. Chem. Inf. Model..
[88] Vincent Le Guilloux,et al. Fpocket: An open source platform for ligand pocket detection , 2009, BMC Bioinformatics.
[89] Olivier Sperandio,et al. FAF-Drugs2: Free ADME/tox filtering tool to assist drug discovery and chemical biology projects , 2008, BMC Bioinformatics.
[90] R. Stevens,et al. The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.
[91] Ali Jazayeri,et al. Intracellular allosteric antagonism of the CCR9 receptor , 2016, Nature.
[92] D Sam Paul,et al. MOLS 2.0: software package for peptide modeling and protein–ligand docking , 2016, Journal of Molecular Modeling.
[93] Thierry Langer,et al. LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..
[94] David S. Goodsell,et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..
[95] B. Neustadt,et al. Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines. , 2007, Bioorganic & medicinal chemistry letters.
[96] W. Patrick Walters,et al. A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.
[97] Weijun Xu,et al. Repurposing Registered Drugs as Antagonists for Protease-Activated Receptor 2 , 2015, J. Chem. Inf. Model..
[98] Ryan G. Coleman,et al. ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..
[99] Igor I. Baskin,et al. Machine Learning Methods for Property Prediction in Chemoinformatics: Quo Vadis? , 2012, J. Chem. Inf. Model..
[100] Gebhard F. X. Schertler,et al. Projection structure of rhodopsin , 1993, Nature.
[101] E. Kostenis,et al. Functional selectivity and dualsteric/bitopic GPCR targeting , 2017, Current opinion in pharmacology.
[102] Arthur Christopoulos,et al. Phase-plate cryo-EM structure of a class B GPCR-G protein complex , 2017, Nature.
[103] X. Xie,et al. Integrated In Silico Fragment-Based Drug Design: Case Study with Allosteric Modulators on Metabotropic Glutamate Receptor 5 , 2017, The AAPS Journal.
[104] Naomi R. Latorraca,et al. Identification of Phosphorylation Codes for Arrestin Recruitment by G Protein-Coupled Receptors , 2017, Cell.
[105] Thomas Lengauer,et al. Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking , 1999, Proteins.
[106] R. Abagyan,et al. Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. , 2010, Journal of the American Chemical Society.
[107] P Willett,et al. Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.
[108] Yong Seo Cho,et al. Novel Scaffold Identification of mGlu1 Receptor Negative Allosteric Modulators Using a Hierarchical Virtual Screening Approach , 2016, Chemical biology & drug design.
[109] Nathan Robertson,et al. Article pubs.acs.org/jmc Identification of Novel Adenosine A 2A Receptor Antagonists by Virtual Screening , 2022 .
[110] David E. Gloriam,et al. Pharmacogenomics of GPCR Drug Targets , 2018, Cell.
[111] K. Chung,et al. Conformational analysis of g protein-coupled receptor signaling by hydrogen/deuterium exchange mass spectrometry. , 2015, Methods in enzymology.
[112] G. Keserű,et al. Fragment-based lead discovery on G-protein-coupled receptors , 2013, Expert opinion on drug discovery.
[113] David E. Gloriam,et al. Trends in GPCR drug discovery: new agents, targets and indications , 2017, Nature Reviews Drug Discovery.
[114] Ruben Abagyan,et al. Structure-Based Ligand Discovery Targeting Orthosteric and Allosteric Pockets of Dopamine Receptors , 2013, Molecular Pharmacology.
[115] S. Rasmussen,et al. Crystal Structure of the β2Adrenergic Receptor-Gs protein complex , 2011, Nature.
[116] Oliver Koch,et al. What Can We Learn from Bioactivity Data? Chemoinformatics Tools and Applications in Chemical Biology Research. , 2017, ACS chemical biology.
[117] Sid Topiol,et al. Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. , 2008, Bioorganic & medicinal chemistry letters.
[118] Ruth Nussinov,et al. Deterministic Pharmacophore Detection Via Multiple Flexible Alignment of Drug-Like Molecules , 2007, RECOMB.
[119] M. Burghammer,et al. Crystal structure of the human β2 adrenergic G-protein-coupled receptor , 2007, Nature.
[120] Sun Choi,et al. Expediting the Design, Discovery and Development of Anticancer Drugs using Computational Approaches. , 2017, Current medicinal chemistry.
[121] A. Doré,et al. Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain , 2014, Nature.
[122] T. S. Kobilka,et al. Cryo-EM structure of the activated GLP-1 receptor in complex with G protein , 2017, Nature.
[123] Harpreet Singh,et al. Software and Web Resources for Computer-Aided Molecular Modeling and Drug Discovery , 2016 .
[124] R Sowdhamini,et al. Molecular modelling of human 5-hydroxytryptamine receptor (5-HT2A) and virtual screening studies towards the identification of agonist and antagonist molecules , 2016, Journal of biomolecular structure & dynamics.
[125] Pekka Tiikkainen,et al. Estimating Error Rates in Bioactivity Databases , 2013, J. Chem. Inf. Model..
[126] Raymond C. Stevens,et al. Structural Basis for Ligand Recognition and Functional Selectivity at Angiotensin Receptor*♦ , 2015, The Journal of Biological Chemistry.
[127] H. V. van Vlijmen,et al. Which Compound to Select in Lead Optimization? Prospectively Validated Proteochemometric Models Guide Preclinical Development , 2011, PloS one.
[128] Anil K. Saxena,et al. Integration on Ligand and Structure Based Approaches in GPCRs , 2017 .
[129] Peter Kolb,et al. Structure-based discovery of β2-adrenergic receptor ligands , 2009, Proceedings of the National Academy of Sciences.
[130] Tudor I. Oprea,et al. WOMBAT: World of Molecular Bioactivity , 2005 .
[131] Jens Meiler,et al. Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator , 2014, Science.
[132] Woody Sherman,et al. Predicting Binding Affinities for GPCR Ligands Using Free-Energy Perturbation , 2016, ACS omega.
[133] Minsup Kim,et al. Incorporating QM and solvation into docking for applications to GPCR targets. , 2016, Physical chemistry chemical physics : PCCP.
[134] Arthur Christopoulos,et al. A kinetic view of GPCR allostery and biased agonism. , 2017, Nature chemical biology.
[135] Philippe Chavatte,et al. Virtual Screening of CB2 Receptor Agonists from Bayesian Network and High‐Throughput Docking: Structural Insights into Agonist‐Modulated GPCR Features , 2013, Chemical biology & drug design.
[136] Jesús A Izaguirre,et al. Characterization of the Anopheles gambiae octopamine receptor and discovery of potential agonists and antagonists using a combined computational-experimental approach , 2014, Malaria Journal.
[137] R. Stevens,et al. How Ligands Illuminate GPCR Molecular Pharmacology , 2017, Cell.
[138] A. Hopkins,et al. Navigating chemical space for biology and medicine , 2004, Nature.
[139] Christopher W Murray,et al. Experiences in fragment-based drug discovery. , 2012, Trends in pharmacological sciences.
[140] Brian K. Shoichet,et al. Structure-Based Discovery of A2A Adenosine Receptor Ligands , 2010, Journal of medicinal chemistry.
[141] T. Lundstedt,et al. Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. , 2001, Biochimica et biophysica acta.
[142] J. Baldwin. The probable arrangement of the helices in G protein‐coupled receptors. , 1993, The EMBO journal.
[143] Luis G Valerio,et al. Chemoinformatics and chemical genomics: potential utility of in silico methods , 2012, Journal of applied toxicology : JAT.
[144] Ruben Abagyan,et al. Structure of the human histamine H1 receptor complex with doxepin , 2011, Nature.
[145] Ajay N. Jain. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..
[146] Sun Choi,et al. In silico classification of adenosine receptor antagonists using Laplacian-modified naïve Bayesian, support vector machine, and recursive partitioning. , 2010, Journal of molecular graphics & modelling.
[147] P. Hawkins,et al. Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.
[148] Isidro Cortes-Ciriano,et al. Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects , 2015 .
[149] Satoshi Niijima,et al. GLIDA: GPCR—ligand database for chemical genomics drug discovery—database and tools update , 2007, Nucleic Acids Res..
[150] J. Qian,et al. Visualization of arrestin recruitment by a G Protein-Coupled Receptor , 2014, Nature.
[151] Stefano Costanzi,et al. Computational studies to predict or explain G protein coupled receptor polypharmacology. , 2014, Trends in pharmacological sciences.
[152] Emmanuel Bresso,et al. GPCRs from fusarium graminearum detection, modeling and virtual screening - the search for new routes to control head blight disease , 2016, BMC Bioinformatics.
[153] A. Hauser,et al. Identification of Histamine H3 Receptor Ligands Using a New Crystal Structure Fragment-based Method , 2017, Scientific Reports.
[154] Manfred Burghammer,et al. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. , 2007, Nature.
[155] Chris de Graaf,et al. Function-specific virtual screening for GPCR ligands using a combined scoring method , 2016, Scientific Reports.
[156] Garth J. Williams,et al. Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser , 2014, Nature.
[157] E. Lionta,et al. Structure-Based Virtual Screening for Drug Discovery: Principles, Applications and Recent Advances , 2014, Current topics in medicinal chemistry.
[158] R. Stevens,et al. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.
[159] A Wlodawer,et al. Inhibitors of HIV-1 protease: a major success of structure-assisted drug design. , 1998, Annual review of biophysics and biomolecular structure.
[160] Petra Schneider,et al. Multi-objective molecular de novo design by adaptive fragment prioritization. , 2014, Angewandte Chemie.
[161] Roderick E Hubbard,et al. Experiences in fragment-based lead discovery. , 2011, Methods in enzymology.
[162] Márton Vass,et al. Multiple fragment docking and linking in primary and secondary pockets of dopamine receptors. , 2014, ACS medicinal chemistry letters.
[163] Woody Sherman,et al. In search of novel ligands using a structure-based approach: a case study on the adenosine A2A receptor , 2016, Journal of Computer-Aided Molecular Design.
[164] Arthur Christopoulos,et al. Improving virtual screening of G protein-coupled receptors via ligand-directed modeling , 2017, PLoS Comput. Biol..
[165] B. Neustadt. Potent, Selective, and Orally Active Adenosine A2A Receptor Antagonists: Arylpiperazine Derivatives of Pyrazolo[4,3‐e]‐1,2,4‐triazolo[1,5‐c]pyrimidines. , 2007 .
[166] J. Reymond. The chemical space project. , 2015, Accounts of chemical research.
[167] M. Cui,et al. In silico prediction of multiple-category classification model for cytochrome P450 inhibitors and non-inhibitors using machine-learning method$ , 2017, SAR and QSAR in environmental research.
[168] Hualiang Jiang,et al. Two disparate ligand-binding sites in the human P2Y1 receptor , 2015, Nature.
[169] Ajay N. Jain,et al. Surflex-Dock: Docking benchmarks and real-world application , 2012, Journal of Computer-Aided Molecular Design.
[170] Tudor I. Oprea,et al. Chemography: the Art of Navigating in Chemical Space , 2000 .
[171] Zhiwei Cao,et al. Study on human GPCR-inhibitor interactions by proteochemometric modeling. , 2013, Gene.
[172] Ruben Abagyan,et al. Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. , 2010, Journal of medicinal chemistry.
[173] Jihye Seong,et al. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist , 2016, Journal of Computer-Aided Molecular Design.
[174] George Khelashvili,et al. GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base , 2010, Bioinform..
[175] Matthew P. Repasky,et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. , 2006, Journal of medicinal chemistry.
[176] Adriaan P. IJzerman,et al. Complementarity between in Silico and Biophysical Screening Approaches in Fragment-Based Lead Discovery against the A2A Adenosine Receptor , 2013, J. Chem. Inf. Model..
[177] Gisbert Schneider,et al. Multidimensional de novo design reveals 5-HT2B receptor-selective ligands. , 2015, Angewandte Chemie.
[178] A. Bayoumi,et al. Biased G Protein-Coupled Receptor Signaling: New Player in Modulating Physiology and Pathology , 2017, Biomolecules & therapeutics.
[179] Alexander Tropsha,et al. Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..
[180] Ruben Abagyan,et al. Spatial chemical distance based on atomic property fields , 2010, J. Comput. Aided Mol. Des..
[181] S. Moro,et al. Advances in Computational Techniques to Study GPCR-Ligand Recognition. , 2015, Trends in pharmacological sciences.
[182] K. Jacobson,et al. Fragment optimization for GPCRs by molecular dynamics free energy calculations: Probing druggable subpockets of the A2A adenosine receptor binding site , 2017, Scientific Reports.
[183] J. Violin,et al. Biased ligands for better cardiovascular drugs: dissecting G-protein-coupled receptor pharmacology. , 2011, Circulation research.
[184] Chaok Seok,et al. Galaxy7TM: flexible GPCR–ligand docking by structure refinement , 2016, Nucleic Acids Res..
[185] Tina Ritschel,et al. Molecular interaction fingerprint approaches for GPCR drug discovery. , 2016, Current opinion in pharmacology.
[186] R. Smits,et al. Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H4 and the ion channel serotonin 5-HT3A , 2011, Bioorganic & medicinal chemistry letters.
[187] Arthur J. Olson,et al. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..
[188] Oliver P. Ernst,et al. Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.
[189] Alexander Tropsha,et al. Comparative Analysis of QSAR‐based vs. Chemical Similarity Based Predictors of GPCRs Binding Affinity , 2016, Molecular informatics.
[190] C. Hoffmann,et al. Intramolecular and Intermolecular FRET Sensors for GPCRs - Monitoring Conformational Changes and Beyond. , 2017, Trends in pharmacological sciences.
[191] Ruben Abagyan,et al. Identifying ligands at orphan GPCRs: current status using structure‐based approaches , 2016, British journal of pharmacology.
[192] R. Cramer,et al. Topomer CoMFA: a design methodology for rapid lead optimization. , 2003, Journal of medicinal chemistry.
[193] S. P. Andrews,et al. Structure‐Based and Fragment‐Based GPCR Drug Discovery , 2014, ChemMedChem.
[194] D. E. Nichols,et al. Crystal Structure of an LSD-Bound Human Serotonin Receptor , 2017, Cell.
[195] Márton Vass,et al. Virtual fragment screening on GPCRs: a case study on dopamine D3 and histamine H4 receptors. , 2014, European journal of medicinal chemistry.
[196] David S Wishart,et al. Introduction to cheminformatics. , 2007, Current protocols in bioinformatics.